PMID- 33530368
OWN - NLM
STAT- MEDLINE
DCOM- 20210726
LR  - 20210726
IS  - 2073-4425 (Electronic)
IS  - 2073-4425 (Linking)
VI  - 12
IP  - 2
DP  - 2021 Jan 26
TI  - Evaluating the Role of Circulating Dendritic Cells in Methimazole-Treated 
      Pediatric Graves' Disease Patients.
LID - 10.3390/genes12020164 [doi]
LID - 164
AB  - Graves' disease (GD) is hyperthyroidism associated with organ-specific autoimmune 
      inflammation. GD occurs more frequently in adults than in children; however, 
      pediatric patients are a therapeutic challenge due to cycles of remissions and 
      relapses requiring constant monitoring at every stage of treatment administered. 
      Dendritic cells (DCs) are considered to be a link between innate and adaptive 
      immunity. DCs, as antigen-presenting cells (APCs), are involved in antigen 
      presentation to T lymphocytes, thereby initiating a shift towards effector cells. 
      In accordance, DCs also participate in the modulation of tolerance to specific 
      antigens. To date, the data on DCs' role in Graves' pathological processes are 
      scarce. Therefore, here, we evaluated the frequencies and role of circulating DCs 
      in GD pediatric patients treated with methimazole. Flow cytometric analysis was 
      implemented to evaluate three subsets of dendritic cells and their correlation 
      with clinical GD-related parameters. We found significantly higher levels of DC 
      subsets in patients at diagnosis. Furthermore, methimazole treatment seemed to 
      effectively reduce subsets of DCs, which, in addition, were found to 
      differentially correlate with thyroid function. Our study shed new light on DCs' 
      role in the pediatric GD pathomechanism. Further studies are required for the 
      mechanistic assessment of DCs' exact role in disease progression and influence on 
      thyroid function.
FAU - Starosz, Aleksandra
AU  - Starosz A
AUID- ORCID: 0000-0003-1084-5747
AD  - Department of Regenerative Medicine and Immune Regulation, Medical University of 
      Bialystok, 15-269 Bialystok, Poland.
FAU - Stozek, Karolina
AU  - Stozek K
AD  - Cardiology Unit, Department of Pediatrics, Endocrinology and Diabetes, Medical 
      University of Bialystok, 15-274 Bialystok, Poland.
FAU - Moniuszko, Marcin
AU  - Moniuszko M
AD  - Department of Regenerative Medicine and Immune Regulation, Medical University of 
      Bialystok, 15-269 Bialystok, Poland.
FAU - Grubczak, Kamil
AU  - Grubczak K
AD  - Department of Regenerative Medicine and Immune Regulation, Medical University of 
      Bialystok, 15-269 Bialystok, Poland.
FAU - Bossowski, Artur
AU  - Bossowski A
AUID- ORCID: 0000-0002-6316-5342
AD  - Cardiology Unit, Department of Pediatrics, Endocrinology and Diabetes, Medical 
      University of Bialystok, 15-274 Bialystok, Poland.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20210126
PL  - Switzerland
TA  - Genes (Basel)
JT  - Genes
JID - 101551097
RN  - 0 (Antithyroid Agents)
RN  - 554Z48XN5E (Methimazole)
SB  - IM
MH  - Age Factors
MH  - Antithyroid Agents/therapeutic use
MH  - Case-Control Studies
MH  - *Cell Count
MH  - Dendritic Cells/*immunology/metabolism
MH  - *Disease Susceptibility
MH  - Graves Disease/*blood/diagnosis/drug therapy/*etiology
MH  - Humans
MH  - Immunophenotyping
MH  - Methimazole/therapeutic use
MH  - Treatment Outcome
PMC - PMC7911035
OTO - NOTNLM
OT  - Graves' disease
OT  - autoimmunity
OT  - dendritic cells
OT  - methimazole
COIS- The authors declare no conflict of interest.
EDAT- 2021/02/04 06:00
MHDA- 2021/07/27 06:00
PMCR- 2021/01/26
CRDT- 2021/02/03 01:01
PHST- 2020/12/13 00:00 [received]
PHST- 2021/01/14 00:00 [revised]
PHST- 2021/01/22 00:00 [accepted]
PHST- 2021/02/03 01:01 [entrez]
PHST- 2021/02/04 06:00 [pubmed]
PHST- 2021/07/27 06:00 [medline]
PHST- 2021/01/26 00:00 [pmc-release]
AID - genes12020164 [pii]
AID - genes-12-00164 [pii]
AID - 10.3390/genes12020164 [doi]
PST - epublish
SO  - Genes (Basel). 2021 Jan 26;12(2):164. doi: 10.3390/genes12020164.